|Published (Last):||7 October 2015|
|PDF File Size:||7.8 Mb|
|ePub File Size:||4.27 Mb|
|Price:||Free* [*Free Regsitration Required]|
Free to read. However, this peptide has proven difficult to target pharmacologically because it is produced by a complex proteolytic pathway, and the secretases involved in its production have additional substrates that are necessary for normal biological functions.
NFAT, normally localized in the cytosol, contains a cryptic nuclear localization signal that is revealed upon dephosphorylation by CaN.
In a recent issue of The Journal of Neuroscience , Hudry et al. They recapitulated AD-phenotypical cell morphology spine loss and dendritic branch simplification in primary cortical neurons by overexpressing constitutively active forms of either CaN or NFAT.
In Hudry et al. As a control, VIVIT with a myristoylation tag, which directed the peptide toward the cell membrane without the ability to act in the nucleus , was not effective in preventing nuclear NFAT accumulation. Collectively, these data indicate that NFAT induces cell morphological changes by its actions in the nucleus. Hudry et al. A cranial window was implanted in the living animals 1 month later and neurites and spines were quantified by multiphoton imaging.
A previous report described an alternative sequence for this pathway Cho et al. These two intersecting pathways presented by Cho et al. In addition, this study has implications for another class of putative AD-therapeutics that target glycogen synthase kinase-3 GSK-3 , which should be revisited in light of the data published by Hudry et al.
GSK-3 inhibitors, therefore, have been investigated as AD therapeutics, but have shown conflicting outcomes in preclinical and clinical trials Hampel et al. In addition, the GSK-3 inhibitor lithium was tested in a randomized, placebo-controlled, phase II clinical trial and showed no benefit to cognition for patients with AD Hampel et al.
Possibly explaining these opposing outcomes, genetic and pharmacological reduction of GSK-3 activity have also been shown to activate NFAT Ohteki et al. If, as shown by Hudry et al. The pathway presented by Hudry et al. In summary, the recent paper by Hudry et al. Editor's Note: These short, critical reviews of recent papers in the Journal , written exclusively by graduate students or postdoctoral fellows, are intended to summarize the important findings of the paper and provide additional insight and commentary.
Read article at publisher's site DOI : Br J Cancer , 10 , 30 Mar Mol Psychiatry , 22 3 , 12 Jul Cited by 10 articles PMID: Neurotherapeutics , 12 1 , 01 Jan Review Free to read. To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Recent history Saved searches. Ayton S 1 ,. Lei P. Affiliations 1 author 1. Share this article Share with email Share with twitter Share with linkedin Share with facebook. Free full text. J Neurosci. PMID: Author information Article notes Copyright and License information Disclaimer. Corresponding author. Open in a separate window.
Figure 1. Go to:. Aging Cell. J Clin Invest. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter week study. J Clin Psychiatry.
GSK3 inhibitors show benefits in an Alzheimer's disease AD model of neurodegeneration but adverse effects in control animals. Neurobiol Dis. Inhibition of the NFAT pathway alleviates amyloid beta neurotoxicity in a mouse model of Alzheimer's disease. GSK-3 in neurodegenerative diseases. Int J Alzheimers Dis. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK J Exp Med. Regulation of NMDA receptor trafficking by amyloid-beta.
Nat Neurosci. Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. NF-AT activation requires suppression of Crm1-dependent export by calcineurin. Footnotes References.
Smart citations by scite. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or contradicted. Lithium suppression of tau induces brain iron accumulation and neurodegeneration. Biometals and their therapeutic implications in Alzheimer's disease. Synaptotoxicity in Alzheimer's disease: the Wnt signaling pathway as a molecular target.
LEI 9456 EM PDF
Changes to the transition metals, zinc, copper, and iron, in AD impact on the molecular mechanisms of disease, and targeting these metals.. Scott Ayton and Peng Lei contributed equally to this work. N Engl J Med. For effective protection of a new variety, five requirements are needed: The lack of differentiation within the 28 traits was expected since specific descriptors for flowers, for example, are most useful for distinguishing between different species; however, in this study all the genotypes belong to C. Hartter DE, Kei A. Kuperstein F, Yavin E. Once published, it becomes the basis for national guidelines.
Mikataxe Here, we present a hypothesis that targeting metals in AD might be an alternative, more tractable, therapeutic strategy. This encouraging trial data has not led to further AD clinical development of compounds that target iron. Once published, it becomes the basis for national guidelines. Recombined lines L1, L2, L6 and L8 obtained values ranging from 1 to 2, and are considered resistant according to Riva-Souza et al. Iron-mediated free-radical formation of signaling lipids in a model system.